Aquestive Therapeutics Overview
- Status
-
Public
- Employees
-
130
- Stock Symbol
-
AQST
- Investments
-
3
- Share Price
-
$1.58
- (As of Friday Closing)
Aquestive Therapeutics General Information
Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Contact Information
- 30 Technology Drive
- Warren, NJ 07059
- United States
Aquestive Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.58 | $1.63 | $0.72 - $2.69 | 61.7M | 348K | -$0.42 |
Aquestive Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 113,815 | 85,291 | 168,517 | 228,609 |
| Revenue | 46,520 | 47,680 | 50,832 | 45,849 |
| EBITDA | (27,126) | (39,679) | (45,537) | (39,450) |
| Net Income | (22,612) | (54,410) | (70,539) | (55,783) |
| Total Assets | 56,994 | 57,070 | 61,993 | 62,884 |
| Total Debt | 45,120 | 57,488 | 56,421 | 40,478 |
Aquestive Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aquestive Therapeutics Comparisons
Industry
Financing
Details
000000
00000
Aquestive Therapeutics Competitors (27)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals | Formerly VC-backed | PA | 000 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Washington, DC | 000 | 00000 | 000000&0 | |
| 000000 | Corporation | Paris, France | 00000 | 000 | 000000000 | 000 |
| 00000000 000000000 | Formerly VC-backed | Pratteln, Switzerland | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Hayward, CA | 00 | 00000 | 000000000 | 00000 |
Aquestive Therapeutics Patents
Aquestive Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230131450-A1 | Oral and nasal compositions and methods of treatment | Pending | 25-Oct-2021 | 00000000000 | 0 |
| US-20230130055-A1 | Pharmaceutical compositions with enhanced stability profiles | Pending | 22-Oct-2021 | 0000000000 | |
| CA-3210706-A1 | Dosage forms having equivalent biocomparable profiles | Pending | 09-Mar-2021 | 000000000 | |
| US-20220347117-A1 | Dosage forms having equivalent biocomparable profiles | Pending | 09-Mar-2021 | 0000000000 | |
| CA-3208345-A1 | Prodrug compositions and methods of treatment | Pending | 15-Jan-2021 | A61K31/137 |
Aquestive Therapeutics Executive Team (13)
Aquestive Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 000000 | Aquestive Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| 0000000 00000 00 | Self | Board Member | 000 0000 |
| 00000 0000 00 | Self | Board Member | 000 0000 |
| 00000 000000000 00 | Self | Board Member | 000 0000 |
| 00000 00000 00 | Aquestive Therapeutics | Chairman & Board Member | 000 0000 |
Aquestive Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Aquestive Therapeutics Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 29-May-2007 | 0000000000 | 00000 | Other Materials | 000 00000 |
| 00000000 (000 | 29-May-2007 | 0000000000 | Other Containers and Packaging | ||
| RespondTV | 26-Jul-2000 | Later Stage VC | 000.00 | Social Content |
Aquestive Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 13, 2021
55.73 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 452
Rank
Percentile
Aquestive Therapeutics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000 | 26-Jul-2000 | 00000 00000 00 | 000.00 | Completed |
|